Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors
Curative Biotechnology Inc. (OTC: CUBT) has appointed Lawrence S. Zaslow as an independent director, enhancing its Board of Directors. Zaslow, a co-founder of BioTheryX, Inc., brings extensive experience in strategic planning, capital raising, and corporate development. His leadership contributed to BioTheryX's $100 million financing round. Curative Biotech focuses on novel treatments for rare diseases, with ongoing programs in infectious disease, neuro oncology, and degenerative eye disease, including its pipeline candidates IMT504, CURB906, and a reformulated Metformin for Age-Related Macular Degeneration.
- Appointment of Lawrence S. Zaslow as independent director enhances corporate governance.
- Zaslow's experience in capital raising and strategic planning expected to strengthen company operations.
- Zaslow's leadership contributed to a successful $100 million financing round at BioTheryX.
- CUBT is not generating revenues, indicating financial challenges.
- Dependence on forward-looking statements raises uncertainty regarding business performance.
Appointment of Independent Director Builds Upon Biotech Expertise
Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee.
Mr. Zaslow co-founded BioTheryX, Inc. (https://biotheryx.com/about-us/), a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years.
During his tenure at BioTheryX Mr. Zaslow had primary responsibility for:
- Strategic and operational planning
- Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals
- Investor relations and public relations
Mr. Zaslow helped position BioTheryX for its recent
Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC (http://www.amphionplc.com/index.php ), engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.
Future Curative Biotechnology Press Releases and Updates
Interested investors and shareholders can be notified of future Press releases and Industry Updates by e-mailing ir@curativebiotech.com
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company’s pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CUBT is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT)
201-454-5845
ir@curativebiotech.com
FAQ
Who is the new independent director at Curative Biotechnology (CUBT)?
What is Lawrence S. Zaslow's experience relevant to Curative Biotechnology (CUBT)?
How does Lawrence S. Zaslow's appointment impact Curative Biotechnology (CUBT)?
What are Curative Biotechnology's key focus areas?
